Description

Agilent Technologies’ Hidden Forensics Surge: TSA Contracts And Global Tenders Drive Momentum!

Agilent Technologies, Inc. reported its second-quarter fiscal 2026 results highlighting a 6.3% core revenue growth to $1.83 billion, exceeding guidance estimates by approximately 80 basis points. This growth was broad-based across key end markets, driven notably by the pharmaceutical sector’s 6% increase, chemicals and advanced materials growing 8%, diagnostics and clinical up 11%, and a more than 50% surge in forensics largely due to new TSA contracts and large tender wins in Asia and Europe. Instrument revenues experienced high single-digit growth, with strong double-digit increases in liquid chromatography (LC), LC/mass spectrometry (MS), and gas chromatography (GC), reflecting continued momentum in replacement cycles and share gains. Operating margin improved by 130 basis points year-over-year to 26.4%, surpassing expectations due to efficiencies from the Ignite Operating System, pricing strategies contributing approximately 200 basis points, and favorable geographic mix skewed towards the Americas. Earnings per share grew 14% to $1.